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TolC and the other members of the outer membrane factor (OMF) family are outer
membrane proteins forming trimeric channels that serve as a conduit for most actively
effluxed substrates in Gram-negative bacteria by providing a key component in a
multitude of tripartite efflux-pumps. Current models of tripartite pump assembly ascribe
substrate selection to the inner-membrane transporter and periplasmic-adapter protein
(PAP) assembly, suggesting that TolC is a passive, non-selective channel. While the
membrane-embedded portion of the protein adopts a porin-like fold, the periplasmic
domain of TolC presents a unique “alpha-barrel” architecture. This alpha-barrel consists
of pseudo-continuous α-helices forming curved coiled-coils, whose tips form α-helical
hairpins, relaxation of which results in a transition of TolC from a closed to an open-
aperture state allowing effective efflux of substrates through its channel. Here, we
analyzed the effects of site-directed mutations targeting the alpha-barrel of TolC, of
the principal tripartite efflux-pump Escherichia coli AcrAB-TolC, on the activity and
specificity of efflux. Live-cell functional assays with these TolC mutants revealed that
positions both at the periplasmic tip of, and partway up the TolC coiled-coil alpha-barrel
domain are involved in determining the functionality of the complex. We report that
mutations affecting the electrostatic properties of the channel, particularly the D371V
mutation, significantly impact growth even in the absence of antibiotics, causing hyper-
susceptibility to all tested efflux-substrates. These results suggest that inhibition of TolC
functionality is less well-tolerated than deletion of tolC, and such inhibition may have
an antibacterial effect. Significantly and unexpectedly, we identified antibiotic-specific
phenotypes associated with novel TolC mutations, suggesting that substrate specificity
may not be determined solely by the transporter protein or the PAP, but may reside at
least partially with the TolC-channel. Furthermore, some of the effects of mutations are
difficult to reconcile with the currently prevalent tip-to-tip model of PAP-TolC interaction
due to their location higher-up on the TolC alpha-barrel relative to the proposed PAP-
docking sites. Taken together our results suggest a possible new role for TolC in vetting
of efflux substrates, alongside its established role in tripartite complex assembly.
Keywords: antibiotic resistance, Gram-negative outer membrane, tripartite efflux pumps, multi-drug efflux pump,
channel protein, substrate specificity, TolC, OMF
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INTRODUCTION
On the list of the World Health Organization’s ten priority
pathogens for which new antibiotics are urgently needed,
six are Gram-negative bacteria (World Health Organization,
2017). These didermic bacteria are characterized by their
lipopolysaccharide-containing outer membrane, which creates
a permeability barrier to decrease cytoplasmic accumulation
of substances, including antibiotics, from the surrounding
environment. The cytoplasmic accumulation of toxic substances
is further decreased by active efflux from within the cell (Fralick
and Burnskeliher, 1994; Nikaido, 1994; Krishnamoorthy et al.,
2017; Westfall et al., 2017). Antibiotic efflux systems therefore
represent attractive targets in overcoming antibiotic resistance.
In Escherichia coli, the tripartite pump AcrAB-TolC is
principally responsible for efflux-mediated multidrug resistance
(Nishino and Yamaguchi, 2001; Sulavik et al., 2001). It
consists of the RND-family transporter AcrB, the outer
membrane-embedded channel-protein TolC and, bridging the
two (Figure 1), the periplasmic adapter protein (PAP) family
member, AcrA (Misra and Bavro, 2009; Symmons et al., 2015;
Du et al., 2018). Deletion of the gene encoding any one of these
three proteins from the chromosome increases susceptibility of
E. coli to many antibiotics (Husain and Nikaido, 2010), as does
mutational inactivation of AcrB or chemical inhibition of AcrB
efflux activity (Husain and Nikaido, 2010; Opperman et al., 2014).
Each individual protein is suggested to play a defined
role within the tripartite assembly. The Resistance-nodulation-
division (RND) transporter AcrB is an inner membrane protein
that forms a homotrimer and has extensive periplasmic domains
that are thought to be responsible for drug binding and
transport, and interaction with partner proteins (Elkins and
Nikaido, 2002; Murakami et al., 2002). Transport itself is driven
by conformational changes induced by proton translocation
through the transmembrane domain (Murakami et al., 2006;
Seeger et al., 2006; Eicher et al., 2014).
The energized inner membrane RND-transporter AcrB is
linked to the outer membrane-bound TolC by the PAP AcrA.
AcrA is a multidomain periplasmic protein, with a hairpin-like
topology, with both N- and C-terminal ends of its polypeptide
chain contributing to each of the 4 principal domains, which
are arranged in a string-like fashion. The membrane proximal
(MPD) domain alongside the neighboring β-barrel and lipoyl
domains are thought to interact with AcrB (Du et al., 2014;
McNeil et al., 2019), while an α-helical coiled-coil hairpin domain
forms an extension, which in all models of assembly extends
beyond AcrB further into the periplasm allowing AcrA to interact
with TolC via an as-yet unconfirmed interface (Mikolosko et al.,
2006; Stegmeier et al., 2006; Lobedanz et al., 2007; Symmons et al.,
2009; Du et al., 2014; Daury et al., 2016; Shi et al., 2019).
Current consensus suggests that TolC provides a gated, but
otherwise passive channel (Zgurskaya et al., 2011), which is highly
FIGURE 1 | Models of AcrAB-TolC interaction. Comparison of the OMF-PAP interaction in “deep-interpenetration” models (left) and the “tip-to-tip” models (right)
derived from the experimental cryo-EM structures of AcrABZ-TolC (based on 5O66.pdb; Wang et al., 2017).
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promiscuous and capable of transporting equally well small drugs
and megadalton-sized repeats-in-toxin (RTX) adhesins across the
outer membrane (Smith et al., 2018).
The TolC from E. coli is the prototypical representative of
the outer-membrane factor (OMF) family (Paulsen et al., 1997),
which is widely spread within Gram-negative bacteria, and also
includes OprM from Pseudomonas aeruginosa, VceC from Vibrio
cholerae and MtrE from Neisseria gonorrhoeae amongst others
(Federici et al., 2005; Janganan et al., 2011; Zgurskaya et al.,
2011; Monlezun et al., 2015; Phan et al., 2015). All of these
are homotrimeric outer membrane proteins consisting of a
transmembrane β-barrel, an extended discontinuous periplasmic
coiled-coil domain and a mixed α-helical/β-stranded equatorial
domain of unknown function (Koronakis et al., 2000; Federici
et al., 2005; Monlezun et al., 2015). Together with the
transmembrane β-barrel, the coiled-coil domain (also known
as the α-barrel) of TolC forms a pseudo-continuous tube
that is occluded at the periplasmic end by converging tips
of the helical hairpins formed by helices H3/H4 and H7/H8
(sometimes referred to as the TolC-hairpin domain). The tips
of these hairpins are held together by a set of strong ion-bridge
interactions, involving residues T152, D153, Y362, and R367 (see
Figure 2). These interactions can be disrupted by mutagenesis
resulting in a spontaneous relaxation of the helical-hairpin
trajectories of the so-called “mobile” helices H7/H8 relative to
the “static” H3/H4 hairpins leading to TolC channel opening
(Andersen et al., 2002a; Bavro et al., 2008; Pei et al., 2011).
Under physiological conditions these interactions are speculated
to be unlocked by interaction with the cognate PAP (in this case
AcrA), and are hence referred to as “primary gates” (Bavro et al.,
2008; Janganan et al., 2013). While the exact mechanism is still a
matter of debate, there are two prevailing models of OMF-PAP
interaction (Symmons et al., 2015). The first model is primarily
based upon biochemical data and involves AcrA-hairpin domain
wrapping around the lower portion of the TolC α-barrel, fitting
into the so called inter-protomer and intra-protomer helical
grooves formed by the H3/H4 and H7/H8 hairpins in a deeply
interpenetrative fashion forming inter-protein helical bundles
with the TolC hairpins (Fernandez-Recio et al., 2004; Stegmeier
et al., 2006; Lobedanz et al., 2007; Tikhonova et al., 2011). The
second model is derived predominantly from cryo-EM structural
data suggesting only a limited interface between the AcrA
hairpins and the tips of the TolC coiled-coils hence it is called
the “tip-to-tip” model of interaction (Xu et al., 2011), and results
in an extended uniform tube (Du et al., 2014; Kim et al., 2015;
Daury et al., 2016; Shi et al., 2019; Figure 1). While most of the
recent cryo-EM (Kim et al., 2015; Daury et al., 2016; Wang et al.,
2017; Tsutsumi et al., 2019) and cryo-tomography structures
(Shi et al., 2019) have favored the tip-to-tip model, there is still
some ambiguity whether deeper interpenetration may take place
transiently during part of the efflux-cycle (Hayashi et al., 2016).
It has long been hypothesized that the specificity to efflux
substrates resides solely within the energized RND-pump
component of the tripartite assembly (Elkins and Nikaido,
2002; Middlemiss and Poole, 2004). Indeed, a number of
crystallographic (Nakashima et al., 2011, 2013; Eicher et al.,
2012) and mutagenesis studies (Middlemiss and Poole, 2004;
Husain et al., 2011; Soparkar et al., 2015) have suggested
that drug selectivity resides within the large cavities of the
AcrB transporter, namely the so-called “proximal” and “distal”
binding pockets, which are separated by the drug-vetting switch-
loop (Nakashima et al., 2011, 2013; Eicher et al., 2012), as
well as by the interprotomer vestibules (Husain et al., 2011).
Furthermore, adaptive mutations selected under direct antibiotic
pressure have been shown to affect not only general regulators
of efflux pump gene expression, but also to specifically affect
the drug binding pocket of AcrB and related transporters
(Blair et al., 2015; Yao et al., 2016), altering the profile of
exported drugs.
The above data points strongly to the primacy of the AcrB (and
RND-transporters in general) in the selection of the substrates
within the tripartite multidrug efflux-assemblies. While the role
of PAPs in substrate selection is less clear, several studies have
highlighted their possible involvement in the case of metal-
transporting RND-pumps (De Angelis et al., 2010; Chacon et al.,
2014) and substrate-dependent activation of both ABC- and
RND-transporter based tripartite assemblies (Tikhonova et al.,
2007; Lin et al., 2009; Verchere et al., 2015). Adding to the
complexity, there is also a notable redundancy amongst PAPs,
which arises from their promiscuous interaction with a number
of RND-partner pumps, allowing for added resilience and an
ability to export similar, but different substrates (Smith and Blair,
2014; McNeil et al., 2019).
In comparison to the transporters and PAPs discussed above,
the role of TolC in selection and vetting of the export cargoes has
remained relatively unexplored. To our knowledge, no conclusive
substrate-specific role has been reported for TolC and the channel
is seen as a passive conduit in terms of efflux specificity. To
address this gap in our understanding of the role of OMFs
in relation to substrate selection and to clarify the mode of
their possible association with its cognate PAPs, in the present
study, we analyzed the predicted solvent-exposed residues of the
lower-portion of the TolC α-barrel, which are likely to engage
the potential PAP-hairpins under both “deep-interpenetration”
and “tip-to-tip” interaction scenarios discussed above. We then
targeted these using site-directed mutagenesis and performed
functional assays on the resulting mutants to evaluate their effect
on the pump activity and substrate selectivity using a range of
clinically relevant antibiotics.
Here, we identify mutations targeting residues of the coiled-
coil interface of TolC α-barrel that impact not just overall
efficiency of efflux, but also alter the specificity of the pump to
several compounds, highlighting a previously underappreciated
role of the OMF channels in vetting the efflux substrates.
MATERIALS AND METHODS
Strains and Plasmids
The kanamycin resistance marker was removed from the
BW25113 tolC::aph Keio strain JW5503 (Baba et al., 2006),
using the pCP20 protocol (Cherepanov and Wackernagel, 1995;
Datsenko and Wanner, 2000), to generate BW1tolC. In order to
clone the tolC gene and for subsequent mutagenesis we generated
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FIGURE 2 | Localisation of the mutated residues discussed within the context of the TolC structure. Onto a single protomer of TolC (1EK9, teal) are mapped the
positions mutated in the current study, shown in stick format and color-coded according to the effect of the respective mutation as determined by growth kinetics
assays. Note that, mutations that have a substrate-specific effect are not localized to a specific region of the TolC α-barrel. Blue: mutation has an antibiotic-specific
effect. Red: mutation presents same phenotype as BW1tolC. Yellow: effect observed is dependent on the substitution. Residues colored in teal: mutation has no
effect. Helices belonging to the adjacent protomers are colored green. Lower-left panel shows the view of the TolC channel from the periplasmic aperture side, with
helices forming the mobile (H7/H8) and static (H3/H4) hairpins being labeled, alongside with the key gating residues T152, D153, Y362, and R367.
a custom plasmid pASK-RM, which was produced by three
rounds of mutagenesis on pASK-IBA13 (IBA Technologies),
as described in the Supplementary Information. The pASK-
tolC plasmid was made by cloning tolC amplified from the
MG1655 chromosome into pASK-RM using the NdeI and
XhoI restriction sites. All mutations were made on the pASK-
tolC plasmid using the Quikchange Lightning site-directed
mutagenesis kit (Agilent), in accordance with the manufacturer’s
instructions. Both the BW25113 wild-type Keio parent strain
and the BW1tolC derivative were transformed with pASK-
RM using the Transformation and Storage Solution (TSS)
method (Chung et al., 1989); BW1tolC was transformed with
pASK-tolC and the mutated plasmids using the TSS method.
All plasmid-containing strains were maintained on Lennox agar
supplemented with 100 µg.ml−1 ampicillin, and cultured in
Lennox broth supplemented with 100 µg.ml−1 ampicillin.
Determination of Minimum Inhibitory
Concentrations (MICs)
All MIC assays were designed to comply with standards set out
by the British Society of Antimicrobial Chemotherapy for MIC
determination by agar dilution (Andrews, 2012). In modification
to the standard method, anhydrotetracycline was added to cooled
molten Iso-Sensitest agar (Oxoid) to a final concentration of
20 ng.ml−1 before dispensing.
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Growth Kinetics Assays
To Iso-Sensitest broth (Oxoid), anhydrotetracycline was added
to a final concentration of 2 ng.ml−1 and the test antibiotic to the
final concentration as required. Single colonies were inoculated
into 2 ml Lennox broth supplemented with 100 µg.ml−1
ampicillin and 2 ng.ml−1 anhydrotetracycline, and incubated at
37◦C with shaking at 200 rpm for 8 h. Bacteria were harvested by
centrifugation (21,000 × g for 5 min) and resuspended to 1/200
the original cell density in Iso-Sensitest broth supplemented with
2 ng.ml−1 anhydrotetracycline. In 96-well plates, 200 µl of the
broth-anhydrotetracycline-test antibiotic solution was inoculated
with 2 µl of the bacterial suspension. Growth was measured on
a Fluostar Optima (BMG Biotech) or Fluostar Omega (BMG
Biotech), at 37◦C with orbital shaking at 200 rpm between read
cycles. The OD600 was measured every 3 min for 8 h using 10
flashes per well per read. The generation time was calculated from
the growth curves, and normalized to the BW1tolC pASK-tolC
strain in the same conditions on the same plate to give a relative
growth rate.
Dye Efflux Assays
Efflux assays using Nile Red as the substrate were modified
from previously published methods (Bohnert et al., 2010; Iyer
et al., 2015). Overnight cultures were diluted 1:1000 in Lennox
broth supplemented with 100 µg.ml−1 ampicillin and 2 ng.ml−1
anhydrotetracycline, and incubated at 37◦C with shaking at
180 rpm for 2 h to reach early exponential phase. Cells
were harvested from 1 ml of this culture by centrifugation at
21,000 × g for 5 min at room temperature and resuspended
in phosphate buffered saline (PBS) to a volume in milliliters
equal to the culture OD600. Carbonyl cyanide m-chlorophenyl
hydrazone (CCCP) and Nile Red were added to 150 µl of
the cell suspensions at final concentrations of 100 µM and
5 µM, respectively, and incubated for 1 h at room temperature.
To remove free Nile Red and CCCP, cells were harvested
(21,000 × g for 5 min at room temperature) and resuspended
in 150 µl fresh PBS. To wells on a black-sided tissue-culture
treated 96-well plate (4titude), 150 µl PBS and 25 µl pre-
loaded cells were added. The OD600 was measured once on a
Fluostar Optima, before the fluorescence was measured with
excitation at 550 nm and emission at 640 nm with 27 s between
readings. Fluorescence was measured for 5 readings before
injection of 25 µl 70 mM glucose and continued for 25 readings
post-injection.
Membrane Protein Analysis
Overnight cultures were diluted 1:1000 in 500 ml Lennox broth
supplemented with 100 µg.ml−1 ampicillin and 2 ng.ml−1
anhydrotetracycline, and incubated at 37◦C with shaking at
180 rpm for 3 h to reach mid exponential phase. Cells were
harvested by centrifugation at 4,000× g for 20 min, resuspended
in 30 ml resuspension buffer (20 mM Tris–HCl pH8.0, 200 mM
NaCl) and lysed on an Emulsiflex C3 homogeniser. Cell debris
were removed by centrifugation at 8,000 × g for 20 min at
4◦C and membranes were harvested from the supernatant by
centrifugation at 100,000× g for 1 h at 4◦C. Purified membranes
were homogenized in 2 ml Tris/glycerol solution (20 mM Tris–
HCl pH6.8, 10% v/v glycerol) and solubilised by addition of
1% n-octyl-β-D-glucopyranoside. Protein concentrations were
determined by Bradford assay in a microtitre plate. An equal
amount of total protein for each sample was resolved by SDS-
PAGE on 10% gels. Proteins were transferred to nitrocellulose
membranes using the iBlot dry transfer system. Membranes were
probed with rabbit-raised anti-TolC polyclonal antibody (kindly
provided by Helen Zgurskaya, Oklahoma State University) and
anti-rabbit alkaline phosphatase-conjugated secondary antibody.
The blot was developed with the chromogenic AP-substrate
BCIP/NBT (Abcam).
RESULTS
In this study, we targeted residues that are solvent-exposed on
the surface of the α-barrel of TolC and its helical hairpins
(H3/H4 and H7/H8), based on the available X-ray structures
of TolC (Koronakis et al., 2000; Bavro et al., 2008; Pei et al.,
2011), to establish their potential impact on the efflux and
drug susceptibilities of the resulting mutant pumps (Figure 2
and Supplementary Table 1). For historical consistency the
numbering of the TolC residues used in the text below is
the accepted one from the PDB entry 1EK9 (Koronakis et al.,
2000) and corresponds to the mature protein lacking the
signal sequence. A full description of the logic of the residue
selection is provided in the “Discussion” section below and in
Supplementary Material).
Minimum Inhibitory Concentration Tests
Identify TolC Mutations Causing
Selective Substrate-Sensitivity and
Vancomycin Sensitivity
A library of mutations in tolC was made on the pASK-
tolC plasmid (see Table 1 for a full-list and Supplementary
Information for the description of location of each mutation). As
the tolC gene was under the control of the tetracycline promoter,
a simple broth MIC assay was used to determine a suitable
concentration of the inducer, anhydrotetracycline (Gossen and
Bujard, 1993), to add for functional assays (data not shown).
As both tested concentrations of anhydrotetracycline (2 and
20 ng.ml−1) caused the MICs of erythromycin and fusidic acid
to be the same for BW1tolC pASK-tolC as for BW25113, it was
decided that anhydrotetracycline should be added at 2 ng.ml−1
for functional assays in broth and at 20 ng.ml−1 for MIC
assays on agar.
Minimum inhibitory concentrations of a variety of substances
against the library of tolC mutations were determined using the
agar dilution method (Table 1 and Supplementary Figure 2).
Of the substances tested, all except vancomycin are reportedly
substrates of AcrAB-TolC (Nishino and Yamaguchi, 2001; Sulavik
et al., 2001). Vancomycin is commonly used to report on the
integrity of the outer membrane permeability barrier, as the
OM is normally impenetrable for it, due to its high molecular
weight and inability to pass via either TolC or constitutively
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TABLE 1 | Minimum inhibitory concentrations for the TolC mutants.
Strain Acf Cam Doc Fus Nal Nov Tet Van
BW25113 pASK-RM 64 4 4096 512 8 512 1 256
BW1tolC pASK-RM 4 0.5 128 4 1 4 0.25 256
BW1tolC pASK-tolC 32 2 4096 64 4 512 0.5 256
D121N 16 2 4096 128 2 512 0.25 256
Q129L 32 2 4096 64 2 512 0.125 128
N145L 8 1 4096 32 0.5 512 0.125 128
R158D 32 2 4096 64 4 512 0.25 128
V198D 32 2 4096 64 4 512 0.25 128
N332L 32 2 4096 128 4 512 0.25 256
N342A 16 2 4096 64 4 512 0.25 256
Y344F 32 2 4096 64 2 512 0.125 64
Q346L 32 2 4096 64 2 512 0.25 256
S350F 2 0.25 128 2 0.5 2 0.25 256
Q352A 32 2 4096 64 4 512 0.25 64
Q352E 8 2 4096 64 2 256 0.25 256
YFRS 4 0.5 256 4 0.5 4 0.25 256
D371V 1 0.25 64 1 0.5 1 0.125 256
D374V 8 2 4096 64 2 512 0.25 256
K383D 8 2 512 64 0.5 512 0.125 128
K383E 16 2 4096 128 4 512 0.25 256
R390E 32 2 4096 64 4 512 0.5 256
RENT 32 2 4096 32 2 512 0.125 32
Minimum inhibitory concentrations in µg.ml−1 of acriflavine (Acf), chloramphenicol (Cam), deoxycholic acid (Doc), fusidic acid (Fus), nalidixic acid (Nal), novobiocin (Nov),
tetracycline (Tet) and vancomycin (Van) against the library of mutants. Bold indicates values significantly different to the complemented strain (≥2 doubling dilutions
difference). Additional visualization of the data presented in provided in Supplementary Figure 2.
expressed porins. Therefore vancomycin susceptibility gives an
indication as to how open or closed the TolC channel may be
(Bavro et al., 2008).
Three mutations (Y344F, Q352A and the R390E/N392T
“RENT” double mutant) caused markedly increased
susceptibility to vancomycin, suggesting that these mutations
cause disruption of the outer membrane permeability barrier at
the level of TolC gating. Of these three mutations, Q352A did not
change susceptibility to any of the other tested substances; while
both Y344F and RENT increased susceptibility to tetracycline
in addition to vancomycin. Notably, while the RENT double
mutant increased susceptibility to vancomycin and tetracycline,
the R390E single mutant did not have any effect on the MIC of
any tested substance. Seven other mutations (D121N, R158D,
V198D, N332L, N342A, Q346L, and K383E) also had no effect as
determined by MIC testing.
Consistent with prior results (Schuster et al., 2016), in this
study, the MIC of rifampicin against both BW25113 pASK-
RM and BW1tolC pASK-RM were the same (data not shown),
indicating that it is not a substrate of the AcrAB-TolC. Having
excluded rifampicin, the D371V mutation caused increased
susceptibility to all of the substrates tested. It was also observed
that this mutation caused a decreased growth rate both in broth
and on agar, colonies and cultures were paler in color than any of
the other strains tested, and colonies were more mucoid with less
well-defined edges.
Of the remaining mutations, each increased susceptibility
to only a single substance – namely tetracycline (Q129L)
and acriflavine (Q352E and D374V). Mutations N145L and
K383D increased susceptibility to acriflavine, nalidixic acid
and tetracycline; while the K383D mutation additionally
increased susceptibility to deoxycholic acid. Meanwhile, and
consistent with prior reports (Augustus et al., 2004; Pei
et al., 2011) both S350F, and the Y362F/R367S (YFRS)
double-mutant increased susceptibility to all tested substrates
except tetracycline.
Growth Kinetics Assays Reveal
Substrate-Specific Effects of the
Mutations
As MIC assays give only an end-point perspective on the growth
of a strain in the presence of antibiotics, growth kinetics assays
were used to derive finer detail regarding the effects of mutations.
Each strain was grown in Iso-Sensitest broth supplemented
with 2 ng.ml−1 anhydrotetracycline and either: no antibiotic,
500 µg.ml-1 deoxycholic acid, 1 µg.ml-1 nalidixic acid, 1 µg.ml-
1 chloramphenicol, 200 µg.ml-1 fusidic acid or 100 µg.ml-1
vancomycin. Growth rates in exponential phase were calculated
as generation time in minutes, and normalized as a percentage
of the growth rate of the BW1tolC pASK-tolC strain on the
same plate to account for plate to plate variability in absolute
growth rates (Table 2 and Supplementary Figure 3). Due to the
phenotype of the D371V mutant showing decreased growth rate
even in the absence of a test substrate, no direct comparisons in
growth rates could be made for this mutation.
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TABLE 2 | Comparison of the relative growth rates of the TolC mutants in different antibiotics.
Cam Doc Fus Nal Nov Vanc
BW25113 pASK-RM 154 160 110 123 126 90
BW1tolC pASK-RM 29 36 19 103 7 109
BW1tolC pASK-tolC 100 100 101 100 100 100
D121N 79 81 116 89 94 85
Q129L 119 104 92 101 96 92
N145L 77 103 117 100 89 101
R158D 84 94 95 82 88 81
V198D 76 121 92 104 81 85
N332L 89 84 104 134 113 80
N342A 94 95 92 135 104 86
Y344F 96 89 75 113 86 89
Q346L 102 106 88 110 109 87
S350F 22 43 34 57 11 118
Q352A 102 98 83 89 92 86
Q352E 100 98 105 116 106 88
YFRS 15 40 N/A 45 N/A 84
D371V 9 27 N/A 33 76 63
D374V 85 91 100 82 87 100
K383D 75 76 105 62 85 78
K383E 111 103 101 103 92 89
R390E 38 76 93 88 N/A 100
RENT 89 85 71 106 N/A 78
Average maximum relative growth rates of strains expressing mutant TolC in the presence of the indicated antibiotics, using the complemented strain as the 100%
reference value. Values given are averages, n = 5 biological replicates except for fusidic acid (n = 4). Bold values are statistically significantly different to the complemented
strain (Welch’s T-test p-value < 0.05).
Measured by relative growth rate, the S350F mutation
increased susceptibility to all efflux substrates tested, but not
to vancomycin (Table 2 and Supplementary Figure 3). The
YFRS mutant grew slower than the BW1tolC pASK-tolC strain
in the presence of each of the efflux substrates tested, though
the mutation had no effect on growth rate in the presence of
vancomycin. Eight of the mutations – N145L, V198D, N342A,
Q346L, Q352A, Q352E, K383E, and RENT – had no effect on
growth rates in the presence of any of the tested substances under
the conditions tested. Significantly, all of the other mutations
(D121N, Q129L, R158D, N332L, Y344F, D374V, K383D, and
R390E) displayed substrate-specific effects on growth rate. The
substrates with which the mutations had an effect were different
for each of these mutations, indicating that the effect is not
due to a global decrease in efflux activity which might have a
greater effect on substrates pumped more rapidly and a lesser
effect on substrates pumped more slowly. None of the three
mutations that caused the MIC of vancomycin to decrease
(namely Y344F, Q352A and the R390E/N392T “RENT”) caused
a change in growth rate in the presence of vancomycin under the
concentration tested, although the R158D, N332L, and K383D
mutations did.
Dye Efflux Assays Reveal Mutations With
Diametrically Opposing Effects on Efflux
To assess efflux activity more directly, the mutations were
used in dye-efflux assays using Nile Red, which fluoresces in
hydrophobic environments such as cell membranes. Cells were
pre-loaded by incubation with both CCCP (to abolish 1p)
and Nile Red. After washing to remove excess CCCP and
Nile Red, fluorescence was measured every 27 s. After five
readings, glucose was injected to re-energize the cells and initiate
efflux activity. Fluorescence measurements were normalized to
fluorescence per unit OD600, to account for variations in number
of cells per sample, and further normalized to a percentage
of initial fluorescence, to account for variation in the starting
fluorescence values. This allows determination of the percentage
of fluorescence that is lost due to efflux activity for each strain
(Figure 3). Two of the mutations (R158D and D371V) showed
an apparently complete loss of efflux activity. Using a cut-off
limit P-value of 0.05 as determined by Bonferroni’s pairwise
T-test, only the K383E mutation (P-value = 0.018) caused a
statistically significant decrease in Nile Red efflux compared
to the BW1tolC pASK-tolC strain; any apparent decrease in
efflux activity for the other mutations was not statistically
significant. Unexpectedly, the RENT double mutation increased
efflux activity (P-value = 0.00012).
Phenotypic Effects Are Not Due to TolC
Protein Levels in the Membrane
To ensure that the observed phenotypic differences were not
due to significantly altered protein expression levels, TolC
expression within the strains showing phenotypic differences
were compared by Western blot. Membrane fractions were
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FIGURE 3 | Efflux activity as determined by Nile Red efflux assays. A value of
100 would indicate complete loss of fluorescence. Each dot represents a
unique biological replicate; error bars represent standard deviation. Values
were normalized first to account for minor differences in OD600 between
samples. The red and blue dotted lines represent efflux efficiency of the
wild-type TolC positive control and the BW1tolC negative control,
respectively. Note that R158D and D371V show efflux decrease similar to the
TolC-deletion control, while “RENT” double-mutant provides statistically
significant increase in efflux efficiency.
harvested from stationary phase cultures, solubilised and the
relative total membrane protein concentration of each sample
measured by Bradford assay. An equal amount of total
membrane protein from each sample was resolved by SDS-PAGE,
transferred to nitrocellulose and probed using polyclonal anti-
TolC antibodies. Alkaline phosphatase-conjugated secondary
antibodies and NBT/BCIP were used to develop the blot. The
blot indicated that BW1tolC pASK-tolC overproduced TolC
protein compared to the wild-type BW25113 pASK-RM strain
(Supplementary Figure 4). Of the mutations assessed, D121N,
S350F, and YFRS showed comparable levels of TolC protein
as the complemented strain. The K383D and R390E mutations
showed lower TolC levels than the complemented strain, but
higher than the wild-type strain. The amount of D371V mutant
TolC protein was substantially lower than the amount of TolC
in the complemented strain, but appeared comparable to the
amount of TolC protein in the wild-type strain. The slight
widening of the bands visible for each strain preparation is
consistent with the full-length unprocessed protein and mature
protein, respectively.
DISCUSSION
In this study, we set out to analyze the effect of a number of point-
mutants of the solvent-accessible residues of the TolC channel
on the efflux activity and substrate specificity. Mutations used
in this study were chosen based on structural predictions that
they would either affect the AcrA-TolC interaction or impact the
propensity of the TolC channel to become open, derived from the
comparative analysis of the open-state (2VDD.pdb, 2VDE.pdb;
Bavro et al., 2008; 2XMN.pdb; Pei et al., 2011) and closed-
state (1EK9.pdb; Koronakis et al., 2000) TolC crystal structures.
We also wanted to characterize the antibiotic profiles of some
residues for which phenotypically pronounced mutations have
been reported earlier, such as R390 (Augustus et al., 2004) and
D121 (Bokma et al., 2006).
Hence the mutants introduced relate to residues which can
be broadly split into the following groups by their location
on the TolC α-barrel and assumed mechanism of action (see
Figure 2 and Supplementary Material): Y362, R367 (tip of
helix H7 and loop-connecting H7 with H8, respectively), –
gating residues (aka “primary gates”) – sealing the tip of the
channel; D371, D374 (H8) – gating residues (secondary gates) –
restricting the lumen of the channel; D121, Q129 (H3), Q352,
K383, R390 (helix7) – intra-protomer groove solvent exposed
residues; V198 – equatorial domain loop; N145 (H3); R158
(H4); N332, N342, Q346 (H7) – inter-protomer groove of TolC;
Y344; S350 – interprotomer interface (H7) potentially impacting
inter-helical packing;
Only one of the mutations tested was not introduced
purposefully – R390E/N392T (RENT) – arose spontaneously
during the process of R390E mutagenesis and was included
due to the possibility of it being a suppressor mutation.
There is no obvious reason why this mutation spontaneously
arose, or why it has a substrate-specific effect on phenotype.
N392 is located at the middle section of H8, which forms
part of the “moving” hairpin H7/H8, however, the location
of the residue is rather far away from the dilation of the
aperture as seen in the available structures, facing partway into
the lumen of the TolC channel. Intriguingly, N392 has been
reported to become more solvent-accessible in the presence
of AcrAB (Krishnamoorthy et al., 2013), consistent with the
possible rearrangement of the H7/H8 hairpin associated with
the TolC channel opening upon complex assembly and AcrA
interaction. While the exact mechanism of its action is difficult
to rationalize at present, it is notable, that position N392 is
located beneath the equatorial domain of TolC, some 30 Å from
the periplasmic tip of the OMF that undergoes dilation. It is
well-established that the equatorial domain is required for TolC
functionality. Specifically, residues 198–214 within the equatorial
domain determine which transporter-PAP pair function with the
OMF (Yamanaka et al., 2007). In addition, the C-terminal part
of the OMF that contributes to the discontinuous equatorial
domain is also involved in regulating the OMF function. Namely,
the C-terminal part of the equatorial domain is required for
functionality in TolC (Yamanaka et al., 2001, 2004); while in
OprM, the C-terminal 22 amino acids, which also form part
of the equatorial domain, are similarly involved in determining
functionality with cognate and non-cognate pumps and PAPs
(Bai et al., 2010, 2014).
Consistent with the importance of the equatorial domain,
several residues we mutated in addition of the aforementioned
N392 exhibit phenotypic effects (D121, N332, N342, and R390)
and lie in direct proximity to it. The D121N mutation had
previously been described from a random mutagenesis study
(Bokma et al., 2006). That study identified this mutation as
enabling TolC to function with MexAB but did not investigate
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the impact of this mutation upon AcrAB-TolC functionality.
Our results establish that the mutation D121N causes a mild
but substrate-specific effect. The effect of the mutation is
difficult to reconcile with a simple increase in the open-state
probability of the TolC channel given the differential antibiotic-
specificity, which should have been the same across the spectrum
of substrates if that was the case. One possible explanation
for the observed effect is that TolC residue D121, which is
close to the equatorial domain and on the external face of
TolC channel, may discriminate between cognate and non-
cognate PAP partner proteins. While this could be achieved
directly through interaction with the PAP-hairpin in the adaptor
wrapping model of interaction, it is unclear how this function
would be achieved in the tip-to-tip model. At the same time,
despite the same considerations applying to the mutation V198D
that is located on the equatorial domain loop, this mutant did not
exhibit any detectable difference in MICs against the WT TolC
under complementation conditions tested.
Although current models of pump function do not attribute
any role for TolC in substrate selection or vetting, it is
apparent from our MIC and growth kinetic data that some of
the mutations tested in this study have an effect for only a
subset of antibiotics and dyes, changing the substrate profile
of the efflux pump complex. This could be for a variety of
reasons. At positions that line the TolC lumen (Q129, Y344,
and D374; see Figure 2), this effect may arise due to changing
the electrostatic and hydrophobicity profiles of the environment
through which a substrate must pass and even direct steric
hindrance, hence affecting the kinetics of substrate passage
through the channel. The same explanation could be at least true
for residues lining the periplasmic tip of TolC (e.g., N145) –
although mutations at the tip region have previously been
reported to decrease the affinity of TolC for its partner proteins
(Tikhonova et al., 2011). However, it seems highly unlikely
that any interaction between the channel and substrate is also
the cause of substrate-specific effects for mutations at positions
mapping to the outside of the channel (D121, R158, N332,
and R390), as the substrate should not directly pass through
or interact with these positions. Some PAP-OMF interactions
have been observed to be naturally substrate-specific, notably
those involving MexJ (Chuanchuen et al., 2002). The MexJK
PAP-transporter pair utilizes either OprM or OpmH dependent
upon the efflux substrate (Chuanchuen et al., 2005). While
there is no suggestion of the possibility of the OMF-swap in
the current study, changes of the state of the TolC channel
could potentially be sensed by the PAPs, and communicated to
the RND pump, which in turn may translate into functional
differences. Indeed, in the RND metal-ion efflux systems such
as ZneCAB and CusCFBA, the PAP component is involved
in loading of the substrate into the transporter protein (Bagai
et al., 2008; De Angelis et al., 2010). While such function
has not been reported for PAPs in multidrug RND-systems, it
may explain how mutations on the external face of the TolC
alpha-barrel might have substrate-specific effects. A change in
the interface presented to the cognate PAP could alter the
conformation of the PAP during its binding either of substrate
or TolC, and thereby exclude certain substrates from being
passed to the transporter within tripartite complex. Given
the location of these mutations on the surface of the alpha-
barrel (Figure 2), such communication would likely necessitate
an interaction between AcrA-hairpin similar to the “adaptor
wrapping” deep-interpenetration model of tripartite assembly
(Figure 1). However, the latest structural data, utilizing cryo-
tomography to assess the AcrAB-TolC complex in its native
cellular trans-envelope state, found evidence of complexes only
in the tip-to-tip conformation (Shi et al., 2019).
The aspartate residues at TolC positions 371 and 374 form two
stacked rings of negative charge, which act as a cation trap and
form the tightest constriction within the TolC lumen (Andersen
et al., 2002b). The lower of these, D371, may be involved
in stabilizing the open state of TolC upon rearrangement of
the ionic network at the periplasmic tip of TolC, namely by
forming a new interaction with R367 (Bavro et al., 2008).
This may partially explain why the R367A mutation causes
hyper-susceptibility to efflux substrates (Augustus et al., 2004)
even though removal of the charge at this position does not
on its own cause constitutive dilation of the TolC channel
(Pei et al., 2011).
Importantly, the overall effect on the cell of the D371V
mutation was not simply a result of loss of TolC function, but
had some additive effect. The deletion of tolC is well tolerated
in laboratory conditions, while the D371V mutation was not.
It is likely that the mutated protein is incapable of fulfilling
its normal role in removal of toxic metabolic products (Ruiz
and Levy, 2014), a task presumably fulfilled by other proteins
in the tolC-deleted strain (Rosner and Martin, 2009). Previously
reported mutation of the aspartate ring D371 was to alanine, the
small-side chain of which does not protrude far into the TolC
lumen, therefore alleviating any steric and charge restrictions
imposed by the aspartate in that position. Indeed, the D371A
mutation was reported not to impact upon either deoxycholic
acid resistance or haemolysin export (Andersen et al., 2002b).
Mutation to valine (D371V) reported here, while superficially
similar is expected to introduce a new rigid steric barrier at
the narrowest part of the channel due to the beta-branching
of the Val side-chain. Hence, this mutation was predicted to
cause disruption of the electrostatic interactions and H-bond
networks at the periplasmic tip, due to the introduction of the
new bulky hydrophobic ring, impacting the existing negatively
charged D374 ring just one helical-turn above in the TolC lumen.
Significantly, modeling the position of the valine sidechains onto
open state structures available suggests that there are severe
steric constraints imposed on them, while they pack tightly
with the aliphatic portion of the R367 in the closed state,
without requiring any notable conformational changes from
the closed structure. It is therefore plausible that the D371V
mutation caused a loss of function by stabilizing the closed-
state of TolC.
In summary, this work indicates that single-substitution
mutations located within, or in close proximity to the equatorial-
domain of TolC can have a negative impact on TolC-function.
This impact does not appear to stem from effects on TolC
expression levels and folding, as it is substrate-specific. These
substrate-specific effects also indicate that the inner-membrane
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transporter/PAP-protein pair is not the sole determinant of
substrate specificity within the tripartite efflux-assemblies, but
significantly, our results hint toward a possible new role
for the OMF proteins in substrate selection and vetting
during efflux events.
At present, these findings can’t be straightforwardly reconciled
with the “tip-to-tip” model of PAP-OMF interaction that is
favored by the recent cryo-EM structural studies, and while
it may be possible that other modes of PAP-OMF interaction
are required at different stages of the efflux process, it is
clear that further investigation is needed to clarify the exact
mechanisms involved.
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